Silo Pharma, Inc. 8-K

What Happened
Silo Pharma, Inc. announced it entered into an asset purchase agreement to acquire certain software marketed as “QwikAgents” and the domain names qwikagents.com, qwikagents.ai, and qwikagents.co. The filing states the agreement was entered into on July 29, 2025 with Many Ads Inc.; as consideration, Silo Pharma issued 2,100,000 shares of its common stock.

Key Details

• Seller: Many Ads Inc.; Buyer: Silo Pharma, Inc.
• Purchased assets: QwikAgents web-based application software and three domain names (qwikagents.com, qwikagents.ai, qwikagents.co).
• Consideration: 2,100,000 shares of common stock (par value $0.0001 per share) issued to the Seller.
• Contract terms: Agreement includes customary representations, warranties and covenants; Seller agreed to indemnify Silo Pharma for misrepresentations, breaches, third‑party infringement claims related to the software, and acts of gross negligence, fraud or intentional misconduct.
• The filing also references the unregistered sale of the equity securities issued in the transaction (Item 3.02).

Why It Matters
This is a non-cash acquisition funded by issuing equity, which increases Silo Pharma’s outstanding shares and can dilute existing shareholders. The company added a specific software product and domain names to its assets, and the seller’s indemnities aim to limit legal and intellectual property risk for Silo Pharma. Investors should note the strategic addition of digital assets and the share issuance when evaluating potential dilution and the company’s evolving business profile.